Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation

Not Applicable

Completed

• Conditions: INFERTILITY; Vitrification; Oocyte Donation; Ovulation Induction; Fertility Preservation
• Interventions: Drug: gonadotropins plus GnRH antagonists; Drug: ganirelix

• Registration Number: NCT01645241
• Lead Sponsor: Institut Universitari Dexeus

Brief Summary

The purpose of this study is to evaluate the clinical pregnancy rate per embryo transfer in oocytes recipients obtained after ovarian stimulation during the luteal phase of oocytes donors . This study will be performed in egg recipients and donors but this type of treatment is meant to be implemented in fertility preservation patients

Detailed Description

Not available

Study Timeline

• Study Start: 2012-07
• Study First Submitted: 2012-07-18
• Study First Submitted QC: 2012-07-19
• Study First Posted: 2012-07-20
• Status Verified: 2013-03
• Primary Completion: 2013-12
• Study Completion: 2013-12
• Last Update Submitted: 2014-10-24
• Last Update Posted: 2014-10-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 15

Inclusion Criteria

• premenopausal women, 18-35 years old, FSH levels < 10 mIU/ml; AFC> 10
• regular cycles
• BMI < 28
• signed informed consent

Recipients:

• Infertile women eligible for oocytes donation
• BMI < 35
• Signed informed consent form

Exclusion Criteria

-Polycystic ovarian syndrome, gonadotropins allergy

Recipients:

• Women eligible for oocytes donation
• BMI >35
• Uncontrolled Endocrine Pathology

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Lutheal phase ovarian stimulation	gonadotropins plus GnRH antagonists	Early luteal phase Controlled ovarian hyperstimulation: we will administer in the 13th-15th cycle day simultaneously 0.25 mg/day of ganirelix to induce luteolysis and FSHr (dose according to BMI and AFC )IU/day for controlled ovarian hyperstimulation until achieving criteria for hCG , to induce final oocyte maturation. Mature oocytes will be vitrified. After warming, oocytes will be inseminated by ICSI with the recipients partners semen sample . Recipient endometrium will be primed with estrogen and progesterone , and embryo transfer will be performed on the 3rd day 3 of embryo cleavage.
Lutheal phase ovarian stimulation	ganirelix	Early luteal phase Controlled ovarian hyperstimulation: we will administer in the 13th-15th cycle day simultaneously 0.25 mg/day of ganirelix to induce luteolysis and FSHr (dose according to BMI and AFC )IU/day for controlled ovarian hyperstimulation until achieving criteria for hCG , to induce final oocyte maturation. Mature oocytes will be vitrified. After warming, oocytes will be inseminated by ICSI with the recipients partners semen sample . Recipient endometrium will be primed with estrogen and progesterone , and embryo transfer will be performed on the 3rd day 3 of embryo cleavage.

Primary Outcome Measures

Name	Time	Method
Pregnancy rate	six weeks after transfer procedure

Secondary Outcome Measures

Name	Time	Method
Number of Mature oocytes	Day of oocyte retrieval

Trial Locations

Locations (1)

Departamento de Obstetricia Ginecologia y Reproducción. Institut Universitari Dexeus; 🇪🇸 Barcelona, Spain